Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Vitamin A is vital to maternal–fetal health and pregnancy outcomes. However, little is known about pregnancy associated changes in maternal vitamin A homeostasis and concentrations of circulating retinol metabolites. The goal of this study was to characterize retinoid concentrations in healthy women (n = 23) during two stages of pregnancy (25–28 weeks gestation and 28–32 weeks gestation) as compared to ≥3 months postpartum. It was hypothesized that plasma retinol, retinol binding protein 4 (RBP4), transthyretin and albumin concentrations would decline during pregnancy and return to baseline by 3 months postpartum. At 25–28 weeks gestation, plasma retinol (−27%), 4-oxo-13-cis-retinoic acid (−34%), and albumin (−22%) concentrations were significantly lower, and all-trans-retinoic acid (+48%) concentrations were significantly higher compared to ≥3 months postpartum in healthy women. In addition, at 28–32 weeks gestation, plasma retinol (−41%), retinol binding protein 4 (RBP4; −17%), transthyretin (TTR; −21%), albumin (−26%), 13-cis-retinoic acid (−23%) and 4-oxo-13-cis-retinoic acid (−48%) concentrations were significantly lower, whereas plasma all-trans-retinoic acid concentrations (+30%) were significantly higher than ≥3 months postpartum. Collectively, the data demonstrates that in healthy pregnancies, retinol plasma concentrations are lower, but all-trans-retinoic acid concentrations are higher than postpartum.

Details

Title
Plasma Retinoid Concentrations Are Altered in Pregnant Women
Author
Czuba, Lindsay C 1   VIAFID ORCID Logo  ; Fay, Emily E 2 ; LaFrance, Jeffrey 1 ; Smith, Chase K 3 ; Shum, Sara 1 ; Moreni, Sue L 2 ; Mao, Jennie 2 ; Isoherranen, Nina 1   VIAFID ORCID Logo  ; Hebert, Mary F 4 

 Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195, USA; [email protected] (L.C.C.); [email protected] (J.L.); [email protected] (S.S.); [email protected] (N.I.) 
 Department of Obstetrics and Gynecology, School of Medicine, University of Washington, Seattle, WA 98195, USA; [email protected] (E.E.F.); [email protected] (S.L.M.); [email protected] (J.M.) 
 Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA 98195, USA; [email protected] 
 Department of Obstetrics and Gynecology, School of Medicine, University of Washington, Seattle, WA 98195, USA; [email protected] (E.E.F.); [email protected] (S.L.M.); [email protected] (J.M.); Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA 98195, USA; [email protected] 
First page
1365
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
20726643
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2649038076
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.